Physician profile
Joel Kramer
NPI 1568464568
$3,990.85
in general payments reported to CMS, 2019-2025
33 companies · $1,183 in 2025
The $1,183 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $991 · 2020: $253 · 2021: $41.00 · 2022: $74.23 · 2023: $712 · 2024: $736 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,631.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $521.10 | 2020-2025 | Veozah |
| Sumitomo Pharma America, INC. | $506.53 | 2023-2025 | Myfembree, Gemtesa |
| Abbvie INC. | $441.36 | 2019-2023 | |
| Sage Therapeutics, LLC | $341.27 | 2023-2025 | Zurzuvae |
| Shield Therapeutics INC | $258.24 | 2024-2025 | |
| Pfizer INC. | $257.73 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $250.15 | 2022-2025 | |
| Hologic Sales and Service, LLC | $186.90 | 2019-2025 | Aptima, Thinprep 2000 Processor, Fluent Fluid Management System |
| Exeltis, USA INC. | $167.78 | 2019-2025 | Slynd |
| Coopersurgical, INC. | $134.48 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $114.20 | 2019-2023 | |
| Mylan Pharmaceuticals INC. | $111.57 | 2019-2022 | |
| Therapeuticsmd, INC. | $103.76 | 2019-2020 | |
| Avion Pharmaceuticals | $79.38 | 2019-2021 | |
| Daiichi Sankyo INC. | $66.10 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $65.46 | 2019 | |
| Dexcom, INC. | $49.20 | 2025 | Dexcom G6 Transmitter |
| Lupin INC. | $34.51 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.54 | 2019 | |
| Lilly USA, LLC | $27.62 | 2019 | |
| Organon LLC | $25.42 | 2024 | |
| Millicent US INC | $25.02 | 2019-2025 | Femring, Intrarosa |
| Medtronic, INC. | $24.60 | 2023 | Truclear |
| Evofem Biosciences, INC. | $19.76 | 2025 | Phexxi, Solosec, Phexx |
| Covidien Lp | $18.63 | 2019 | |
| Duchesnay USA Incorporated | $17.80 | 2019 | |
| Merck Sharp & Dohme LLC | $17.65 | 2024 | Gardasil, Gardasil 9 |
| Mission Pharmacal Company | $16.97 | 2019 | |
| Amgen INC. | $16.96 | 2025 | Evenity |
| Avation Medical, INC. | $16.89 | 2025 | Vivally System |
| Meditrina | $16.42 | 2021 | |
| Novo Nordisk INC | $13.56 | 2023 | Wegovy |
| Allergan, INC. | $13.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.